New launch for clinical labs, Beckman Coulter DxI 9000 raises the bar in immunoassay throughput

With its DxI 9000 Access Immunoassay Analyzer, Danaher’s Beckman Coulter is targeting high-volume clinical labs that need faster, more efficient immunoassay workflows. The system promises higher throughput, a smaller footprint and automated features aimed at easing staffing pressures.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 10:53 AM ET. Details in the imprint.

Beckman Coulter's new DxI 9000 Access Immunoassay Analyzer is designed to push immunoassay throughput for busy clinical laboratories while shrinking the system footprint and reducing hands-on interaction. The analyzer, which Beckman Coulter positions as its next-generation high-throughput immunoassay platform, targets hospital and reference labs that are struggling with staffing constraints and rising test volumes.

What the DxI 9000 is built to do for high-volume labs

The DxI 9000 is an automated immunoassay analyzer built around Beckman Coulter's chemiluminescent Access assay technology, and the company emphasizes that the system is engineered for higher throughput and operational efficiency compared with its predecessor immunoassay platforms. According to Beckman Coulter product materials, the analyzer can process up to 215 tests per hour on a single module, with scalable configurations intended for very high-volume labs that need continuous, walkaway operation, and it supports an expanding menu of routine and specialty immunoassays for applications such as infectious disease, cardiac markers, thyroid function and fertility testing according to the official product page. The system is configured as a fully enclosed analyzer that handles sample loading, reagent management and waste automatically, aiming to free up technologist time in laboratories that may be operating with fewer staff than before the pandemic.

Beckman Coulter highlights a number of workflow-oriented features in the DxI 9000 that go beyond pure throughput to address everyday bottlenecks in immunoassay testing. The analyzer includes large on-board reagent capacity and continuous access for both samples and consumables so that staff can load and unload items without stopping the run, and the company also points to extended calibration stability and quality control processes designed to minimize manual interventions during a shift. In practice, the combination of high hourly test capacity, broad assay menu, and automation of routine steps such as reagent handling and waste disposal is aimed at reducing turnaround times for common test panels and making it easier for labs to maintain service levels during periods of high demand.

System design also targets physical constraints in the lab: the DxI 9000 is promoted as having a reduced footprint relative to previous Beckman Coulter analyzers with similar throughput, which can matter in hospitals where bench space is at a premium. The analyzer is meant to be integrated into Beckman Coulter's broader ecosystem of automation and information systems, enabling connectivity with track-based pre-analytical systems and middleware for sample and data management. For lab directors, the ability to fit a higher-capacity immunoassay analyzer into a constrained layout while keeping it connected to existing automation infrastructure can be a deciding factor when replacing older platforms.

The launch of the DxI 9000 comes as clinical labs face sustained pressure to do more with fewer technologists, a trend that has been documented by industry groups and manufacturers alike. Beckman Coulter's parent company Danaher has repeatedly pointed to clinical diagnostics as a core business area, and new platforms such as the DxI 9000 are intended to refresh the installed base and support menu expansion in areas like high-sensitivity cardiac troponin and infectious disease testing. With healthcare providers investing in laboratory modernization after the pandemic exposed weaknesses in diagnostic capacity, a system that promises higher throughput, better uptime and reduced manual workload is likely to be closely evaluated by large hospital networks and commercial labs.

From a competitive standpoint, the DxI 9000 enters a mature market where rivals such as Roche, Abbott and Siemens already offer high-throughput immunoassay analyzers with broad assay menus and automation options. Beckman Coulter's strategy with the DxI 9000 appears to focus on incremental yet meaningful improvements in throughput, walkaway time and footprint, coupled with a strong emphasis on uptime and service, rather than on radical new assay technologies. For lab customers, the decision to adopt the DxI 9000 will likely come down to how well these incremental improvements translate into lower cost per test, faster turnaround times and smoother daily operations in comparison with incumbent systems.

Within Danaher, Beckman Coulter is one of the larger diagnostics operating companies and new platforms like the DxI 9000 support the group's broader diagnostics portfolio alongside molecular and clinical chemistry systems. Danaher recently underscored the importance of diagnostics and life sciences, including Beckman Coulter, as drivers of long-term growth in its investor communications, with management pointing to continued innovation and installed-base expansion as key levers as outlined in Danaher investor materials. Shares of Danaher (US2358511028) traded on the NYSE at around $250 in early June 2026.

DxI 9000 Access Immunoassay Analyzer in brief

• Product: DxI 9000 Access Immunoassay Analyzer
• Manufacturer: Danaher Corp. (Beckman Coulter)
• Category: New Release / Launch - Clinical immunoassay analyzer
• Launch date: 2023 (market introduction announced)
• MSRP / Price: Not publicly disclosed; capital instrument pricing typically via quotation
• Availability: Available to clinical laboratories in multiple regions via Beckman Coulter sales channels
• Target audience: High-volume hospital and reference laboratories needing automated immunoassay testing
• Key differentiator / USP: High immunoassay throughput with a reduced footprint and workflow-focused automation features

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.